BG106626A - Таблета с директно пресовано полимерно ядро - Google Patents

Таблета с директно пресовано полимерно ядро Download PDF

Info

Publication number: BG106626A
Authority: BG; Bulgaria
Prior art keywords: tablet; core; coating; poly; aliphatic amine
Prior art date: 1999-10-19

Application number

BG106626A

Other languages

Bulgarian (bg)

English (en)

Inventor

Joseph Tyler

John Petersen

Original Assignee

Geltex Pharmaceuticals Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-19

Filing date

2002-04-19

Publication date

2003-03-31

2002-04-19 Application filed by Geltex Pharmaceuticals Inc. filed Critical Geltex Pharmaceuticals Inc.

2003-03-31 Publication of BG106626A publication Critical patent/BG106626A/bg

Links

229920000642 polymer Polymers 0.000 title claims abstract description 48
238000007907 direct compression Methods 0.000 title description 2
238000000576 coating method Methods 0.000 claims abstract description 43
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims abstract description 43
239000011248 coating agent Substances 0.000 claims abstract description 41
239000000203 mixture Substances 0.000 claims abstract description 26
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
239000003826 tablet Substances 0.000 claims description 103
KHNXRSIBRKBJDI-UHFFFAOYSA-N Sevelamer hydrochloride Chemical compound Cl.NCC=C.ClCC1CO1 KHNXRSIBRKBJDI-UHFFFAOYSA-N 0.000 claims description 26
229960003027 sevelamer hydrochloride Drugs 0.000 claims description 26
229920000083 poly(allylamine) Polymers 0.000 claims description 16
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 13
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
239000008119 colloidal silica Substances 0.000 claims description 10
235000021355 Stearic acid Nutrition 0.000 claims description 8
239000007891 compressed tablet Substances 0.000 claims description 8
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 8
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
239000008117 stearic acid Substances 0.000 claims description 8
229920002678 cellulose Polymers 0.000 claims description 7
239000001913 cellulose Substances 0.000 claims description 7
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 4
239000013543 active substance Substances 0.000 claims description 3
229920002518 Polyallylamine hydrochloride Polymers 0.000 claims description 2
UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 claims description 2
DYUWTXWIYMHBQS-UHFFFAOYSA-N n-prop-2-enylprop-2-en-1-amine Chemical compound C=CCNCC=C DYUWTXWIYMHBQS-UHFFFAOYSA-N 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims 3
125000006686 (C1-C24) alkyl group Chemical group 0.000 claims 1
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims 1
239000003513 alkali Substances 0.000 claims 1
239000004014 plasticizer Substances 0.000 claims 1
238000000034 method Methods 0.000 abstract description 13
239000002952 polymeric resin Substances 0.000 abstract description 6
229920003002 synthetic resin Polymers 0.000 abstract description 6
230000000887 hydrating effect Effects 0.000 abstract description 3
239000004480 active ingredient Substances 0.000 description 11
239000000126 substance Substances 0.000 description 11
239000011347 resin Substances 0.000 description 9
229920005989 resin Polymers 0.000 description 9
239000003814 drug Substances 0.000 description 8
239000000243 solution Substances 0.000 description 8
229940124597 therapeutic agent Drugs 0.000 description 7
239000008199 coating composition Substances 0.000 description 6
238000009472 formulation Methods 0.000 description 6
229910019142 PO4 Inorganic materials 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
239000007884 disintegrant Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
238000002156 mixing Methods 0.000 description 3
229960003693 sevelamer Drugs 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000007916 tablet composition Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
229920002873 Polyethylenimine Polymers 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000003529 anticholesteremic agent Substances 0.000 description 2
229940127226 anticholesterol agent Drugs 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000003086 colorant Substances 0.000 description 2
229940126534 drug product Drugs 0.000 description 2
229940088679 drug related substance Drugs 0.000 description 2
238000001035 drying Methods 0.000 description 2
-1 for example Substances 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002547 new drug Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
238000012430 stability testing Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
229920002911 Colestipol Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010034972 Photosensitivity reaction Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
229960002604 colestipol Drugs 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
201000005991 hyperphosphatemia Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000036211 photosensitivity Effects 0.000 description 1
239000004848 polyfunctional curative Substances 0.000 description 1
229940020428 renagel Drugs 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
238000013112 stability test Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000002522 swelling effect Effects 0.000 description 1
230000009182 swimming Effects 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000010257 thawing Methods 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Inorganic Chemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG106626A 1999-10-19 2002-04-19 Таблета с директно пресовано полимерно ядро BG106626A (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16025899P	1999-10-19	1999-10-19
US17422700P	2000-01-03	2000-01-03
PCT/US2000/028548 WO2001028527A2 (en)	1999-10-19	2000-10-13	Direct compression polymer tablet core

Publications (1)

Publication Number	Publication Date
BG106626A true BG106626A (bg)	2003-03-31

Family

ID=26856737

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG106626A BG106626A (bg)	1999-10-19	2002-04-19	Таблета с директно пресовано полимерно ядро

Country Status (29)

Country	Link
EP (1)	EP1239837B1 (is)
JP (4)	JP4942271B2 (is)
KR (1)	KR100794427B1 (is)
CN (1)	CN1202812C (is)
AR (1)	AR026067A1 (is)
AT (1)	ATE286386T1 (is)
AU (1)	AU778262B2 (is)
BG (1)	BG106626A (is)
BR (1)	BRPI0015061B8 (is)
CA (1)	CA2387915C (is)
CZ (1)	CZ20021344A3 (is)
DE (1)	DE60017285T2 (is)
EA (1)	EA200200387A1 (is)
EE (1)	EE200200209A (is)
ES (1)	ES2235969T3 (is)
HK (1)	HK1049451B (is)
HU (1)	HUP0203334A2 (is)
IL (1)	IL149146A0 (is)
IS (1)	IS6343A (is)
MX (1)	MXPA02003684A (is)
MY (1)	MY125495A (is)
NO (1)	NO20021827L (is)
NZ (1)	NZ518334A (is)
PL (1)	PL364888A1 (is)
PT (1)	PT1239837E (is)
SK (1)	SK5412002A3 (is)
TR (1)	TR200201087T2 (is)
TW (1)	TWI225413B (is)
WO (1)	WO2001028527A2 (is)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE286386T1 (de) *	1999-10-19	2005-01-15	Genzyme Corp	Direktkomprimierter tablettenkern auf polymerbasis
US7767768B2 (en)	2003-11-03	2010-08-03	Ilypsa, Inc.	Crosslinked amine polymers
US7385012B2 (en)	2003-11-03	2008-06-10	Ilypsa, Inc.	Polyamine polymers
US7459502B2 (en)	2003-11-03	2008-12-02	Ilypsa, Inc.	Pharmaceutical compositions comprising crosslinked polyamine polymers
US7608674B2 (en)	2003-11-03	2009-10-27	Ilypsa, Inc.	Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7335795B2 (en)	2004-03-22	2008-02-26	Ilypsa, Inc.	Crosslinked amine polymers
US7449605B2 (en)	2003-11-03	2008-11-11	Ilypsa, Inc.	Crosslinked amine polymers
CA2551528A1 (en) *	2003-12-31	2005-07-21	Genzyme Corporation	Enteric coated aliphatic amine polymer bile acid sequestrants
ES2453048T3 (es)	2004-03-30	2014-04-03	Relypsa, Inc.	Polímeros de unión de ión y usos de los mismos
US7985418B2 (en) *	2004-11-01	2011-07-26	Genzyme Corporation	Aliphatic amine polymer salts for tableting
AU2012200480B2 (en) *	2004-11-01	2014-10-16	Genzyme Corporation	"Aliphatic amine polymer salts for tableting"
AU2006227429A1 (en) *	2005-03-17	2006-09-28	Amgen Inc.	Methods of decreasing calcification
US8986669B2 (en)	2005-09-02	2015-03-24	Genzyme Corporation	Method for removing phosphate and polymer used therefore
HUE026628T2 (en) *	2005-09-15	2016-06-28	Genzyme Corp	Pouches for amine polymers
CA2749074A1 (en) *	2006-09-01	2008-05-29	Usv Limited	Process for the preparation of sevelamer hydrochloride and formulation thereof
EP2066293A2 (en)	2006-09-29	2009-06-10	Genzyme Corporation	Amide dendrimer compositions
US8163799B2 (en)	2006-12-14	2012-04-24	Genzyme Corporation	Amido-amine polymer compositions
WO2009034540A1 (en) *	2007-09-11	2009-03-19	Ranbaxy Laboratories Limited	Pharmaceutical composition of sevelamer
DE102008030046A1 (de) *	2008-06-25	2009-12-31	Ratiopharm Gmbh	Kompaktiertes Polyallylamin-Polymer
BRPI0918499A2 (pt)	2008-09-02	2015-12-01	Usv Ltd	polímeros reticulados
US20100330175A1 (en) *	2009-06-24	2010-12-30	Jobdevairakkam Christopher N	Cross-linked polyallylamine tablet core
WO2010149794A2 (en) *	2009-06-26	2010-12-29	Combino Pharm, S.L.	Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane)
ES2350999B1 (es) *	2009-06-26	2011-12-07	Combino Pharm, S.L.	Nueva composición farmacéutica comprendiendo hidrocloruro de poli (alilamin-co-n,n'-dialil-1,3-diamino-2-hidroxi propano).
EP2490675B1 (en) *	2009-10-22	2019-01-23	Synthon B.V.	Pharmaceutical compositions of sevelamer
EP2545907A1 (en)	2011-07-15	2013-01-16	Combino Pharm, S.L.	Aqueous wet granulation process for cross-linked polyallylamine polymers
TW201400146A (zh) *	2012-06-05	2014-01-01	Takeda Pharmaceutical	有核錠
CN102908325B (zh) *	2012-11-12	2014-07-30	南京生命能科技开发有限公司	一种碳酸司维拉姆药用片剂组合物及其制备方法
CN107412166B (zh) *	2017-08-08	2020-03-24	同济大学	一种纳米复合吸附磷材料及其制备与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2110166C (en) *	1991-07-03	2002-11-05	Robert Wu-Wei Shen	Tableting of colestipol hydrochloride
US5496545A (en) *	1993-08-11	1996-03-05	Geltex Pharmaceuticals, Inc.	Phosphate-binding polymers for oral administration
TW592727B (en) *	1997-04-04	2004-06-21	Chugai Pharmaceutical Co Ltd	Phosphate-binding polymer preparations
JP3389493B2 (ja) *	1997-04-04	2003-03-24	中外製薬株式会社	リン酸結合性ポリマー製剤
US6083497A (en) *	1997-11-05	2000-07-04	Geltex Pharmaceuticals, Inc.	Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
TW568788B (en) *	1998-10-12	2004-01-01	Chugai Pharmaceutical Co Ltd	Polymer combining with phosphoric acid and preparation containing the same
ATE286386T1 (de) *	1999-10-19	2005-01-15	Genzyme Corp	Direktkomprimierter tablettenkern auf polymerbasis

2000
- 2000-10-13 AT AT00972191T patent/ATE286386T1/de active
- 2000-10-13 PL PL00364888A patent/PL364888A1/xx unknown
- 2000-10-13 WO PCT/US2000/028548 patent/WO2001028527A2/en not_active Ceased
- 2000-10-13 KR KR1020027005018A patent/KR100794427B1/ko not_active Expired - Lifetime
- 2000-10-13 NZ NZ518334A patent/NZ518334A/en not_active IP Right Cessation
- 2000-10-13 CN CNB008146071A patent/CN1202812C/zh not_active Expired - Lifetime
- 2000-10-13 HU HU0203334A patent/HUP0203334A2/hu unknown
- 2000-10-13 EP EP00972191A patent/EP1239837B1/en not_active Expired - Lifetime
- 2000-10-13 MX MXPA02003684A patent/MXPA02003684A/es active IP Right Grant
- 2000-10-13 HK HK03101656.0A patent/HK1049451B/zh not_active IP Right Cessation
- 2000-10-13 AU AU10887/01A patent/AU778262B2/en not_active Expired
- 2000-10-13 PT PT00972191T patent/PT1239837E/pt unknown
- 2000-10-13 EE EEP200200209A patent/EE200200209A/xx unknown
- 2000-10-13 DE DE60017285T patent/DE60017285T2/de not_active Expired - Lifetime
- 2000-10-13 CZ CZ20021344A patent/CZ20021344A3/cs unknown
- 2000-10-13 TR TR2002/01087T patent/TR200201087T2/xx unknown
- 2000-10-13 SK SK541-2002A patent/SK5412002A3/sk unknown
- 2000-10-13 IL IL14914600A patent/IL149146A0/xx unknown
- 2000-10-13 BR BRPI0015061A patent/BRPI0015061B8/pt not_active IP Right Cessation
- 2000-10-13 CA CA002387915A patent/CA2387915C/en not_active Expired - Fee Related
- 2000-10-13 JP JP2001531357A patent/JP4942271B2/ja not_active Expired - Lifetime
- 2000-10-13 ES ES00972191T patent/ES2235969T3/es not_active Expired - Lifetime
- 2000-10-13 EA EA200200387A patent/EA200200387A1/ru unknown
- 2000-10-17 TW TW089121646A patent/TWI225413B/zh not_active IP Right Cessation
- 2000-10-18 AR ARP000105456A patent/AR026067A1/es unknown
- 2000-10-18 MY MYPI20004885A patent/MY125495A/en unknown
2002
- 2002-04-15 IS IS6343A patent/IS6343A/is unknown
- 2002-04-18 NO NO20021827A patent/NO20021827L/no not_active Application Discontinuation
- 2002-04-19 BG BG106626A patent/BG106626A/bg unknown
2011
- 2011-12-29 JP JP2011290234A patent/JP5583110B2/ja not_active Expired - Lifetime
2014
- 2014-01-21 JP JP2014008451A patent/JP5903111B2/ja not_active Expired - Lifetime
2015
- 2015-09-03 JP JP2015173635A patent/JP2016000753A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2003512317A (ja)	2003-04-02
CA2387915C (en)	2007-04-17
ATE286386T1 (de)	2005-01-15
PL364888A1 (en)	2004-12-27
EA200200387A1 (ru)	2002-10-31
MXPA02003684A (es)	2002-08-30
BR0015061A (pt)	2002-07-23
IS6343A (is)	2002-04-15
HK1049451B (zh)	2005-12-16
NZ518334A (en)	2003-08-29
JP2014065749A (ja)	2014-04-17
AU1088701A (en)	2001-04-30
SK5412002A3 (en)	2002-09-10
EE200200209A (et)	2003-06-16
CN1202812C (zh)	2005-05-25
CA2387915A1 (en)	2001-04-26
NO20021827L (no)	2002-05-29
PT1239837E (pt)	2005-05-31
JP4942271B2 (ja)	2012-05-30
AU778262B2 (en)	2004-11-25
CN1382041A (zh)	2002-11-27
JP2012067132A (ja)	2012-04-05
JP2016000753A (ja)	2016-01-07
NO20021827D0 (no)	2002-04-18
EP1239837A2 (en)	2002-09-18
EP1239837B1 (en)	2005-01-05
AR026067A1 (es)	2002-12-26
BRPI0015061B8 (pt)	2021-05-25
JP5583110B2 (ja)	2014-09-03
WO2001028527A3 (en)	2002-01-03
MY125495A (en)	2006-08-30
TR200201087T2 (tr)	2002-08-21
TWI225413B (en)	2004-12-21
ES2235969T3 (es)	2005-07-16
DE60017285D1 (de)	2005-02-10
BRPI0015061B1 (pt)	2016-03-22
HUP0203334A2 (hu)	2003-02-28
WO2001028527A2 (en)	2001-04-26
HK1049451A1 (en)	2003-05-16
DE60017285T2 (de)	2005-12-08
IL149146A0 (en)	2002-11-10
JP5903111B2 (ja)	2016-04-13
KR100794427B1 (ko)	2008-01-16
CZ20021344A3 (cs)	2002-08-14
KR20020059629A (ko)	2002-07-13

Publication	Publication Date	Title
US9931358B2 (en)	2018-04-03	Direct compression polymer tablet core
JP5583110B2 (ja)	2014-09-03	直接圧縮ポリマー錠剤コア
US20080292697A1 (en)	2008-11-27	Direct compression polymer tablet core
KR100456202B1 (ko)	2004-11-09	인산 결합성 중합체 제제
DK2490675T3 (en)	2019-04-29	Pharmaceutical compositions with sevelamer
EP2545907A1 (en)	2013-01-16	Aqueous wet granulation process for cross-linked polyallylamine polymers
CA2576135C (en)	2011-12-06	Direct compression polymer tablet core